is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The presentation will be addressing the reality and challenges of global epidemy of diabetes, with focus on complications caused by diabetic eye disease and will discuss how related risks could be mitigated. While diabetes as such is threating up to 20% of populations, while the ME region being particularly impacted, there is a number of severe comorbidities representing additional burden to diabetic patients. One with a most catastrophic consequences to quality of life of patients is diabetic eye disease.
Our company Aireen has dedicated its efforts to fight diabetic eye disease by leveraging the power of AI.
Key learning objectives:
COMEN Aireen DR is medical device SW based on artificial intelligence. It provides non-invasive, pain-less screening of chronic diseases by analysing digital images of the retina. The retina is the only place in the human body where blood vessels can be seen by the naked eye. Artificial intelligence is cutting-edge breakthrough technology which allows for the precise identification of changes to the retina. It does so using the unique neural network models which COMEN Aireen DR has created on the basis of over 1 million images which have been annotated in collaboration with leading retina specialists from prestigious eye clinics. COMEN Aireen DR has also been a registered medical device since 2020, launched onto the European Union market.